Intelligence ยท Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors โ phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ searchable for business development and competitive intelligence.
-
Hyperpolarized 13C-Pyruvate injection
Hospital Authority, Hong Kong
Gynecologic Cancer
1 trial -
Hypofractionated radiation/chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
I-131-CLR1404 Injection
Cellectar Biosciences
Glioma
1 trial -
IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, Faslodex 250 mg solution for injection., JZP598
Jazz Pharmaceuticals Ireland Limited
Breast cancer patients including those with locally advanced (unresectable) or metastatic HER2-positive, HR-positive breast cancer
1 trial -
IMC-M113V
Immunocore Ireland Limited
Chronic HIV infection
1 trial -
IMCIVREE 10 mg/ml solution for injection
Disc Medicine
ROHHAD syndrome
1 trial -
IMD-1041
Lxo Ireland Designated Activity Company
Chronic Obstructive Pulmonary Disease
1 trial -
INFLIXIMAB , TOCILIZUMAB , Cosentyx 300 mg solution for injection in pre-filled pen, ADALIMUMAB
Pari Pharma GmbH
TAkayasu ARteritiS
1 trial -
ION373, Artificial Cerebrospinal Fluid (aCSF) for injection
IONIS PHARMACEUTICALS INC
Alexander Disease
1 trial -
IONIS-AGT-LRx
IONIS PHARMACEUTICALS INC
Chronic Heart Failure With Reduced Ejection Fraction
1 trial -
IPN10200 placebo, Powder for solution for injection, DYSPORT 500 UNITES SPEYWOOD, poudre pour solution injectable
Ipsen
Upper limb spasticity after stroke or traumatic brain injury
1 trial -
IPTACOPAN, Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023)
Novartis Pharmaceuticals
active antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis
1 trial -
IR Viloxazine
SUPERNUS PHARMACEUTICALS, INC.
Attention-Deficit/Hyperactivity Disorder (ADHD)
1 trial -
IRINOTECAN, CALCIUM LEVOFOLINATE, ivonescimab, FOLINIC ACID, OXALIPLATIN, PACLITAXEL, FLUOROURACIL
Ningbo Cancer Hospital
Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)
1 trial -
IRINOTECAN, FOLINIC ACID, FLUOROURACIL, DOMVANALIMAB, FLUOROURACIL, ZIMBERELIMAB
CERO THERAPEUTICS HOLDINGS, INC.
stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma
1 trial -
ISATUXIMAB
Pari Pharma GmbH
Isatuximab in type I cryoglobulinaemia: A prospective pilot study
1 trial -
IVERMECTIN
The George Institute
Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality.
1 trial -
IW-1973
Akebia Europe Limited
Heart Failure With Preserved Ejection Fraction
1 trial -
Iberdomide, Iberdomide, Iberdomide, Iberdomide, Dexamethasone Tablets BP 2.0mg, Iberdomide, Iberdomide, Iberdomide, Dexamethasone 2mg Tablets , Iberdomide, Iberdomide, DARZALEX 1800 mg solution for injection, Iberdomide, Iberdomide, Iberdomide, Dexamethason-ratiopharmยฎ 4 mg Tabletten
Celgene Europe Limited
Multiple Myeloma
1 trial -
Ibezapolstat
Acurx Pharmaceuticals
Clostridium Difficile Infection
1 trial -
Ibezapolstat
Acurx Pharmaceuticals
Clostridium Difficile Infection Recurrence
1 trial -
Ibrutinib
United Therapeutics Europe Ltd
Asymptomatic COVID-19 Infection Laboratory-Confirmed
1 trial -
Ifetroban Injection
CUMBERLAND PHARMACEUTICALS INC
Hepatorenal Syndrome
1 trial -
Ifinatamab deruxtecan
Daiichi Sankyo
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources